// App-Quantinova.ai

5571.0 : Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).

Researchers

Presenter

  • Joseph Schonhoft

Principal Investigators

  • Audrey Gill

  • Ryon P Graf

  • Adam Jendrisak

  • Ethan Barnett

  • Hannah Benoliel

  • Emily Carbone

  • Alisa Tubbs

  • Sarah Orr

  • Jiyun Byun

  • Rick Wenstrup

  • Howard I. Scher

Medical Centers

  • Epic Sciences, Inc., San Diego, CA

  • Epic Sciences, Inc., San Diego, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved